Relapse detection in the Danish surveillance program of patients with clinical stage I seminoma: a nationwide study
DOI:
https://doi.org/10.2340/1651-226X.2025.42281Keywords:
Testicular cancer, germ cell cancer, seminoma, serum tumor markers, active surveillance, follow-upAbstract
Background and purpose: Active surveillance is a recommended management strategy for patients with clinical stage I (CSI) seminoma. This study aims to identify patterns of relapse detection methods in an unselected population-based cohort of CSI patients and provide evidence for a risk-adapted follow-up program.
Patients/materials and methods: A total of 924 patients with CSI seminoma were identified in the prospective Danish Testicular Cancer database. Retrospectively collected clinical data were used for descriptive analyses of patterns in detection methods. Additionally, we explored a risk-adapted surveillance approach based on recently identified risk factors for relapse, classifying patients into low- and non-low-risk groups.
Results: At 60 months, the 5-year cumulative relapse risk was 16%, with 146 relapses during surveillance. Relapses were detected by imaging alone in 71% of cases, imaging combined with elevated serum tumor markers (STMs) in 18%, isolated elevation of STMs in 8%, and by self-referral due to symptoms in 3%. No relapses were detected by abnormal findings at a physical examination. In total, 134 (92%) relapses were localized to retroperitoneal lymph nodes, primarily without additional spread. The 5-year relapse risk in patients with low risk of relapse was 9% compared to 28% in patients in the non-low-risk group.
Interpretation: This study highlights that the surveillance program can detect relapses at an early stage. Reduction of visits and omission of routine physical examinations can safely be considered for patients with a low risk of relapse, while further research is needed to optimize follow-up and treatment for patients at higher risk of relapse.
Downloads
References
Znaor A, Skakkebaek NE, Rajpert‐De Meyts E, Kuliš T, Laversanne M, Gurney J, et al. Global patterns in testicular cancer incidence and mortality in 2020. Int J Cancer. 2022;151(5):692–8.
https://doi.org/10.1002/ijc.33999 DOI: https://doi.org/10.1002/ijc.33999
Trabert B, Chen J, Devesa SS, Bray F, McGlynn KA. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973–2007. Andrology. 2015;3(1):4–12.
https://doi.org/10.1111/andr.293 DOI: https://doi.org/10.1111/andr.293
Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(4):362–75.
https://doi.org/10.1016/j.annonc.2022.01.002 DOI: https://doi.org/10.1016/j.annonc.2022.01.002
Mortensen MS, Lauritsen J, Gundgaard MG, Agerbæk M, Holm NV, Christensen IJ, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014;66(6):1172–8.
https://doi.org/10.1016/j.eururo.2014.07.001 DOI: https://doi.org/10.1016/j.eururo.2014.07.001
Zequi S C, da Costa WH, Santana TBM, Favaretto RL, Sacomani CAR, Guimaraes GC. Bilateral testicular germ cell tumours: a systematic review. BJU Int. 2012;110(8):1102–9.
https://doi.org/10.1111/j.1464-410X.2012.11056.x DOI: https://doi.org/10.1111/j.1464-410X.2012.11056.x
Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, et al. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. Eur Urol. 2023;84(3):289–301. DOI: https://doi.org/10.1016/j.eururo.2023.04.010
https://doi.org/10.1093/annonc/mdy217
Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018;29(8):1658–86.
https://doi.org/10.1093/annonc/mdy217 DOI: https://doi.org/10.1093/annonc/mdy217
National Comprehensive Cancer Network. Testicular cancer (Version 2.2024) [Internet]. [cited 2024 Oct 22]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf
Vesprini D, Chung P, Tolan S, Gospodarowicz M, Jewett M, O’Malley M, et al. Utility of serum tumor markers during surveillance for stage I seminoma. Cancer. 2012;118(21):5245–50.
https://doi.org/10.1002/cncr.27539 DOI: https://doi.org/10.1002/cncr.27539
Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, et al. The value of tumour markers in the detection of relapse—lessons learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci. 2023;50:57–60.
https://doi.org/10.1016/j.euros.2023.01.013
Joffe JK, Cafferty FH, Murphy L, Rustin GJS, Sohaib SA, Gabe R, et al. Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: results from a randomized, phase III, noninferiority trial (TRISST). J Clin Oncol. 2022;40(22):2468–78.
https://doi.org/10.1200/JCO.21.01199 DOI: https://doi.org/10.1200/JCO.21.01199
Conduit C, Lewin J, Weickhardt A, Lynam J, Wong S, Grimison P, et al. Patterns of relapse in Australian patients with clinical stage 1 testicular cancer: utility of the Australian and New Zealand urogenital and prostate cancer trials Group surveillance recommendations. JCO Oncol Pract. 2023;19(11):973–80.
https://doi.org/10.1200/OP.23.00191 DOI: https://doi.org/10.1200/OP.23.00191
Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015;33(1):51–7.
https://doi.org/10.1200/JCO.2014.56.2116 DOI: https://doi.org/10.1200/JCO.2014.56.2116
Nayan M, Jewett MAS, Hosni A, Anson-Cartwright L, Bedard PL, Moore M, et al. Conditional risk of relapse in surveillance for clinical stage I testicular cancer. Eur Urol. 2017;71(1):120–7.
https://doi.org/10.1016/j.eururo.2016.07.013 DOI: https://doi.org/10.1016/j.eururo.2016.07.013
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7. DOI: https://doi.org/10.1016/S0140-6736(07)61602-X
https://doi.org/10.1136/bmj.39335.541782.AD DOI: https://doi.org/10.1136/bmj.39335.541782.AD
Wagner T, Toft BG, Engvad B, Lauritsen J, Kreiberg M, Bandak M, et al. Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study. BMJ Open. 2019;9(10):e033713.
https://doi.org/10.1136/bmjopen-2019-033713 DOI: https://doi.org/10.1136/bmjopen-2019-033713
Kier MGG, Lauritsen J, Almstrup K, Mortensen MS, Toft BG, Rajpert-De Meyts E, et al. Screening for carcinomain situ in the contralateral testicle in patients with testicular cancer: a population-based study. Ann Oncol. 2015;26(4):737–42.
https://doi.org/10.1093/annonc/mdu585 DOI: https://doi.org/10.1093/annonc/mdu585
Wagner T, Toft BG, Lauritsen J, Bandak M, Christensen IJ, Engvad B, et al. Prognostic factors for relapse in patients with clinical stage I testicular seminoma: a nationwide, population-based cohort study. J Clin Oncol. 2023;42(1):81–9.
https://doi.org/10.1200/JCO.23.00959 DOI: https://doi.org/10.1200/JCO.23.00959
Wagner T, Toft BG, Lauritsen J, Bandak M, Christensen IJ, Engvad B, et al. Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: a nationwide, population-based cohort study. Eur J Cancer. 2024;202:114025.
https://doi.org/10.1016/j.ejca.2024.114025 DOI: https://doi.org/10.1016/j.ejca.2024.114025
Kreiberg M, Bandak M, Lauritsen J, Andersen KK, Skøtt JW, Johansen C, et al. Psychological stress in long-term testicular cancer survivors: a Danish nationwide cohort study. J Cancer Survivors. 2020;14(1):72–9.
https://doi.org/10.1007/s11764-019-00835-0 DOI: https://doi.org/10.1007/s11764-019-00835-0
Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology Clinical Practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28(20):3388–404.
https://doi.org/10.1200/JCO.2009.26.4481 DOI: https://doi.org/10.1200/JCO.2009.26.4481
Stephenson A, Eggener SE, Bass EB, Chelnick DM, Daneshmand S, Feldman D, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019;202(2):272–81.
https://doi.org/10.1097/JU.0000000000000318 DOI: https://doi.org/10.1097/JU.0000000000000318
ANZUP Cancer Trials Group Limited. ANZUP Cancer Trials Group Limited: surveillance recommendations [Internet]. 2021 [cited 2024 Oct 22]. Available from: https://anzup.org.au/recommendations-and-resources/
Bobrowski A, Anson-Cartwright L, Kuhathaas K, Jiang DM, Chung P, Bedard P, et al. Role of lactate dehydrogenase in identifying relapse for patients with stage I testicular cancer on surveillance. J Urol. 2022;208(6):1250–8.
https://doi.org/10.1097/JU.0000000000002931 DOI: https://doi.org/10.1097/JU.0000000000002931
Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, et al. The value of tumour markers in the detection of relapse—lessons learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci. 2023;50:57–60.
https://doi.org/10.1016/j.euros.2023.01.013 DOI: https://doi.org/10.1016/j.euros.2023.01.013
Fankhauser CD, Christiansen AJ, Rothermundt C, Cathomas R, Wettstein MS, Grossmann NC, et al. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer. 2022;126(8):1140–4.
https://doi.org/10.1038/s41416-021-01643-z DOI: https://doi.org/10.1038/s41416-021-01643-z
Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277–84.
https://doi.org/10.1056/NEJMra072149 DOI: https://doi.org/10.1056/NEJMra072149
Hiester A, Che Y, Lusch A, Kuß O, Niegisch G, Lorch A, et al. Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA/B (PRIMETEST). Eur Urol. 2023;84(1):25–31.
https://doi.org/10.1016/j.eururo.2022.10.021 DOI: https://doi.org/10.1016/j.eururo.2022.10.021
Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, et al. Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy. J Clin Oncol. 2023;41(16):3009–18.
https://doi.org/10.1200/JCO.22.00624 DOI: https://doi.org/10.1200/JCO.22.00624
Heidenreich A, Paffenholz P, Hartmann F, Seelemeyer F, Pfister D. Retroperitoneal lymph node dissection in clinical stage IIA/B metastatic seminoma: results of the COlogne trial of retroperitoneal lymphadenectomy in metastatic seminoma (COTRIMS). Eur Urol Oncol. 2024;7(1):122–7.
https://doi.org/10.1016/j.euo.2023.06.004 DOI: https://doi.org/10.1016/j.euo.2023.06.004
Mortensen MS, Lauritsen J, Kier MGG, Bandak M, Appelt AL, Agerbæk M, et al. Late relapses in stage I testicular cancer patients on surveillance. Eur Urol. 2016;70(2):365–71.
https://doi.org/10.1016/j.eururo.2016.03.016 DOI: https://doi.org/10.1016/j.eururo.2016.03.016
Daugaard G, Lauritsen J, Bandak M, Agerbæk M, Als AB, Dysager L, et al. Use of risk factors to select adjuvant therapy versus surveillance for testicular nonseminoma and seminoma germ cell tumors. Eur Urol Focus. 2024;10(3):359–60.
https://doi.org/10.1016/j.euf.2024.06.001 DOI: https://doi.org/10.1016/j.euf.2024.06.001
Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27(7):1299–304.
https://doi.org/10.1093/annonc/mdw164 DOI: https://doi.org/10.1093/annonc/mdw164
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Niklas B. Lindahl, Jakob Lauritsen, Thomas Wagner, Gedske Daugaard, Mikkel Bandak
This work is licensed under a Creative Commons Attribution 4.0 International License.
